Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

In 2023, Autumn was diagnosed with Fanconi anemia, a rare and incurable genetic disorder. For the past month, 18 local high ...

Stem cell technology could revolutionize fertility, offering hope for infertile couples, same-sex partners, and genetic ...

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus ...

A surge in walking pneumonia cases is raising concerns among doctors. Learn how to recognize symptoms and protect yourself ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Jannik Sinner has accepted a three-month suspension from the game after reaching a settlement in his doping case. The men’s world no.1, who defended his Australian Open crown last month, will be ...

A new effort is underway to legalize not just medical marijuana but recreational use, too. But is that the best route forward ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Iga Swiatek, Jannik Sinner, Simona Halep and Tara Moore have had different experiences after testing positive for a banned ...

Leukemia is a leading cause of death among children in India, with over 30,000 cases diagnosed annually. Early diagnosis is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...